The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk ...
AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...
US FDA approves AstraZeneca’s Imfinzi for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer: Cambridge, UK Saturday, May 30, 2026, 13:00 Hrs [IST] AstraZene ...
Gross hematuria in a younger adult prompted rapid urologic evaluation, underscoring that bladder cancer can present before ...
The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...
A Tata Memorial Hospital-led BART trial across four Indian centres over eight years found that modern radiotherapy after bladder cancer surgery is safe and reduces pelvic recurrence by over 50%. The ...
Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results